{"result": {"id": "b02d3553-0b6c-4f4c-acf1-5a28b88e31c9", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>中华内科杂志<|>ORGANIZATION<|>A medical journal publishing research on internal medicine, including the 2023 study on gout treatments referenced in the text.\")  \n##\n(\"entity\"<|>糖皮质激素<|>ORGANIZATION<|>A class of anti-inflammatory drugs (e.g., prednisone) used for gout prevention but with risks like hyperglycemia and osteoporosis.\")  \n##\n(\"entity\"<|>关节感染<|>EVENT<|>A contraindication for corticosteroid injections, requiring exclusion before treatment.\")  \n##\n(\"entity\"<|>高血压<|>EVENT<|>A potential adverse effect of glucocorticoid use mentioned in the text.\")  \n##\n(\"entity\"<|>高血糖<|>EVENT<|>A metabolic side effect associated with corticosteroid therapy.\")  \n##\n(\"entity\"<|>高血脂<|>EVENT<|>A documented risk of prolonged glucocorticoid administration.\")  \n##\n(\"entity\"<|>水钠潴留<|>EVENT<|>A fluid-related complication of corticosteroid treatment.\")  \n##\n(\"entity\"<|>胃肠道出血<|>EVENT<|>A serious adverse effect linked to NSAID use.\")  \n##\n(\"entity\"<|>骨质疏松<|>EVENT<|>A long-term complication of glucocorticoid therapy.\")  \n##\n(\"entity\"<|>降尿酸治疗<|>EVENT<|>Therapeutic process to lower urate levels, often triggering gout flares initially.\")  \n##\n(\"entity\"<|>慢性尿酸盐肾病<|>EVENT<|>A kidney condition treated first with non-drug therapies per the text.\")  \n##\n(\"relationship\"<|>中华内科杂志<|>痛风急性发作<|>The journal published the 2023 clinical guidelines on gout management referenced in the text.<|>4)  \n##\n(\"relationship\"<|>糖皮质激素<|>高血压<|>Glucocorticoids like prednisone can induce hypertension as a side effect.<|>7)  \n##\n(\"relationship\"<|>糖皮质激素<|>高血糖<|>Corticosteroid use is linked to elevated blood sugar levels.<|>7)  \n##\n(\"relationship\"<|>糖皮质激素<|>骨质疏松<|>Prolonged glucocorticoid therapy increases osteoporosis risk.<|>8)  \n##\n(\"relationship\"<|>非甾体抗炎药<|>胃肠道出血<|>NSAIDs may cause gastrointestinal bleeding as a severe adverse effect.<|>7)  \n##\n(\"relationship\"<|>降尿酸治疗<|>痛风急性发作<|>Urate-lowering therapy often triggers acute gout flares during initial months.<|>9)  \n##\n(\"relationship\"<|>关节感染<|>糖皮质激素<|>Joint infection must be ruled out before corticosteroid injections.<|>6)  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752165362, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 627, "prompt_tokens": 3657, "total_tokens": 4284, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3584}, "prompt_cache_hit_tokens": 3584, "prompt_cache_miss_tokens": 73}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 效果差，可给予关 节腔内或肌肉注射糖皮质激素，如复方倍他米松和 曲安奈德，但需排除关节感染，并避免短期内反复 注射 。应用糖皮质激素注意高血压、高血糖、高血 脂、水钠潴留、感染、胃肠道出血、骨质疏松等不良 反应。\n（四）痛风急性发作预防治疗\n　　　降尿酸治疗期间易导致反复出现急性发作症  状，可给予预防治疗 。在初始降尿酸治疗的 3~6 个  月，口服小剂量秋水仙碱 0.5 mg，1~2 次/d 。当秋水  仙碱无效或存在用药禁忌时，考虑低剂量非甾体抗  炎药作为预防性治疗 。上述两药使用存在禁忌或  疗效不佳时，亦可应用小剂量泼尼松（5~ 10 mg/d）\n\n表2    常用非甾体抗炎药的用法和用量[9]\n\n药物\t半衰期 （h）\t起效时间\n（h）\t环氧化酶选择性\t常用推荐剂量\n依托考昔\t约 22\t1\t特异性环氧化酶?2 抑制剂\t60~ 120 mg，1 次/d\n艾瑞昔布\t约 20\t2\t特异性环氧化酶?2 抑制剂\t100 mg，2 次/d\n塞来昔布\t8~ 12\t2~3\t特异性环氧化酶?2 抑制剂\t200 mg，2 次/d\n双氯芬酸\t约 2\t1/3~ 1\t非特异性环氧化酶抑制剂\t50 mg，3 次/d\n醋氯芬酸\t约 4\t1.5~3\t非特异性环氧化酶抑制剂\t100 mg，2 次/d\n布洛芬\t1.8~3.5\t1~2\t非特异性环氧化酶抑制剂\t200 mg，3 次/d\n吲哚美辛\t约 2\t1/2~2\t非特异性环氧化酶抑制剂\t50 mg，3 次/d\n酮洛芬\t1.5~2.5\t0.5~2\t非特异性环氧化酶抑制剂\t50 mg，3 次/d\n萘普生\t10~ 18\t2~4\t非特异性环氧化酶抑制剂\t250 mg，3 次/d\n洛索洛芬\t1~ 1.5\t0.5\t非特异性环氧化酶?2 抑制剂\t60 mg，3 次/d\n美洛昔康\t约 20\t4.9~6\t非特异性环氧化酶?2 抑制剂\t7.5 mg，2 次/d\n吡罗昔康\t30~60\t3~5\t非特异性环氧化酶?2 抑制剂\t10 mg，2 次/d\n\n\n\n\n·  1074   ·                                                           中华内科杂志 2023 年 9 月第 62 卷第 9 期    Chin J Intern Med, September 2023, Vol. 62, No. 9\n\n\n　预防发作，但应注意糖皮质激素长期应用的副作 用 。 目前有研究认为，采用小剂量起始、缓慢滴定 的药物降尿酸方案，明显减少痛风发作，可代替药 物预防治疗。\n（五）其他治疗\n　　　1. 慢性尿酸盐肾病：一旦确诊即开始非药物治 疗，疗效不佳者根据尿\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>复方倍他米松<|>ORGANIZATION<|>A corticosteroid used for joint or muscle injections to treat inflammation, with potential side effects like hypertension and infection.\")  \n##\n(\"entity\"<|>曲安奈德<|>ORGANIZATION<|>A glucocorticoid injected into joints or muscles to reduce inflammation, requiring caution due to risks like infection and osteoporosis.\")  \n##\n(\"entity\"<|>秋水仙碱<|>ORGANIZATION<|>An oral medication used at low doses (0.5 mg) to prevent gout attacks during initial urate-lowering therapy.\")  \n##\n(\"entity\"<|>非甾体抗炎药<|>ORGANIZATION<|>A class of drugs (e.g., celecoxib, ibuprofen) used for gout prevention when colchicine is contraindicated or ineffective.\")  \n##\n(\"entity\"<|>泼尼松<|>ORGANIZATION<|>A glucocorticoid (5–10 mg/day) used as an alternative for gout prevention when other therapies fail.\")  \n##\n(\"entity\"<|>依托考昔<|>ORGANIZATION<|>A COX-2 selective NSAID with a 22-hour half-life, dosed at 60–120 mg once daily for inflammation.\")  \n##\n(\"entity\"<|>艾瑞昔布<|>ORGANIZATION<|>A COX-2 inhibitor (100 mg twice daily) with a 20-hour half-life, used for pain and inflammation.\")  \n##\n(\"entity\"<|>塞来昔布<|>ORGANIZATION<|>COX-2 selective NSAID (200 mg twice daily) with an 8–12 hour half-life for managing gout symptoms.\")  \n##\n(\"entity\"<|>双氯芬酸<|>ORGANIZATION<|>Non-selective COX inhibitor (50 mg three times daily) with a short half-life (~2 hours) for acute pain.\")  \n##\n(\"entity\"<|>醋氯芬酸<|>ORGANIZATION<|>Non-selective COX inhibitor (100 mg twice daily) with a 4-hour half-life, used for inflammatory conditions.\")  \n##\n(\"entity\"<|>布洛芬<|>ORGANIZATION<|>Common NSAID (200 mg three times daily) with a short half-life (1.8–3.5 hours) for pain and inflammation.\")  \n##\n(\"entity\"<|>吲哚美辛<|>ORGANIZATION<|>Non-selective COX inhibitor (50 mg three times daily) with rapid onset (~30 minutes) for gout.\")  \n##\n(\"entity\"<|>酮洛芬<|>ORGANIZATION<|>NSAID (50 mg three times daily) with a very short half-life (1.5–2.5 hours) for acute inflammation.\")  \n##\n(\"entity\"<|>萘普生<|>ORGANIZATION<|>Long-acting NSAID (250 mg three times daily) with a 10–18 hour half-life for sustained relief.\")  \n##\n(\"entity\"<|>洛索洛芬<|>ORGANIZATION<|>COX-2 preferential NSAID (60 mg three times daily) with rapid onset (~0.5 hours).\")  \n##\n(\"entity\"<|>美洛昔康<|>ORGANIZATION<|>Long-acting NSAID (7.5 mg twice daily) with COX-2 preference and 20-hour half-life.\")  \n##\n(\"entity\"<|>吡罗昔康<|>ORGANIZATION<|>NSAID (10 mg twice daily) with a very long half-life (30–60 hours) for chronic inflammation.\")  \n##\n(\"entity\"<|>痛风急性发作<|>EVENT<|>Recurrent inflammatory episodes during urate-lowering therapy, preventable with colchicine or NSAIDs.\")  \n##\n(\"relationship\"<|>秋水仙碱<|>痛风急性发作<|>Low-dose colchicine (0.5 mg) is used to prevent gout attacks during initial urate-lowering therapy.<|>8)  \n##\n(\"relationship\"<|>非甾体抗炎药<|>痛风急性发作<|>NSAIDs serve as an alternative to colchicine for preventing gout flares when contraindications exist.<|>7)  \n##\n(\"relationship\"<|>泼尼松<|>痛风急性发作<|>Low-dose prednisone is a third-line option for gout prevention when other drugs fail.<|>6)  \n##\n(\"relationship\"<|>复方倍他米松<|>曲安奈德<|>Both are injectable glucocorticoids used for joint/muscle inflammation but carry risks like infection.<|>5)  \n##\n(\"relationship\"<|>依托考昔<|>塞来昔布<|>Both are COX-2 selective NSAIDs with similar uses but differing half-lives and dosing.<|>6)  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_cb1ab2bdc34ff22610405b6c2cefa6f55e38477888a7bd123732c0252f2cf962_v2"}